Retatrutide (GLP-3): Complete Guide to Dosing, Results, and Side Effects

[Nelson Vergel]

Curated By Nelson Vergel | ExcelMale.com | Updated March 2026

Key Takeaways Retatrutide is a first-in-class triple hormone receptor agonist (GLP-1 + GIP + glucagon) from Eli Lilly, currently in Phase 3 clinical trials under the TRIUMPH program. In Phase 3 (TRIUMPH-4), participants on the 12 mg dose lost an average of 28.7% of their body weight at 68 weeks, the highest weight loss ever recorded for any obesity medication. The glucagon receptor component differentiates retatrutide from semaglutide and tirzepatide by increasing resting energy expenditure and promoting hepatic fat oxidation. Liver fat reduction reached 82-86% at higher doses, with over 85% of treated participants achieving normal liver fat levels. Retatrutide is NOT FDA-approved. It remains investigational and is legally available only through clinical trials. FDA submission is expected late 2026 with potential approval in 2027.

What If One Weekly Injection Could Outperform Everything on the Market?​

Can a single peptide that hits three metabolic targets simultaneously deliver better weight loss than Ozempic and Mounjaro combined? That's the question driving one of the most closely watched drug development programs in obesity medicine right now. Retatrutide, Eli Lilly's investigational triple hormone receptor agonist, targets GLP-1, GIP, and glucagon receptors all at once. Early clinical trials suggest it may produce weight loss that rivals bariatric surgery, while also clearing fatty liver disease and improving cardiovascular risk markers.

For men on testosterone replacement therapy (TRT), the metabolic implications are particularly relevant. Many TRT patients struggle with stubborn visceral fat despite optimized hormone levels. Standard GLP-1 medications like semaglutide have helped, but concerns about muscle loss and GI tolerability have tempered enthusiasm. Retatrutide's triple mechanism introduces glucagon receptor activation to the equation, which boosts resting energy expenditure and may preferentially target fat stores over lean tissue.

In this guide, you'll learn how retatrutide works at the receptor level, what the clinical data actually shows across Phase 2 and Phase 3 trials, how it stacks up against existing GLP-1 and dual-agonist drugs, what side effects to watch for (including a newly identified safety signal), and what practical considerations matter most for men focused on body composition optimization.

What Is Retatrutide? Understanding the Triple Agonist​

Retatrutide (LY3437943) is a synthetic peptide engineered to simultaneously activate three hormone receptors that regulate hunger, blood sugar, and energy balance: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. This makes it the first "triple agonist" or "triagonist" to reach advanced clinical development.

Think of it in layers. Semaglutide (Ozempic/Wegovy) activates one receptor: GLP-1. Tirzepatide (Mounjaro/Zepbound) activates two: GLP-1 and GIP. Retatrutide adds a third target, glucagon, creating what researchers describe as a more comprehensive metabolic response. Each layer introduces additional weight loss mechanisms beyond appetite suppression alone.

The molecule is a single continuous helical peptide conjugated to a fatty diacid moiety, giving it a half-life of about six days and enabling once-weekly subcutaneous injection. Compared to the body's own hormones, retatrutide is roughly 8.9 times more potent at the GIP receptor and somewhat less potent at the GLP-1 and glucagon receptors (0.4 and 0.3 times, respectively). This potency profile is intentional: strong GIP activation drives metabolic benefits while the moderated GLP-1 and glucagon activity helps balance efficacy with tolerability.

GLP-1 vs. GLP-3: Clearing Up the Terminology​

You'll see retatrutide referred to as a "GLP-3" in peptide communities and online forums. This is informal shorthand, not an official pharmacological classification. The "3" refers to the three receptor targets, not a separate GLP receptor type. There is no GLP-3 receptor in human physiology. When someone mentions "GLP-3 peptide," they mean a triple agonist like retatrutide that acts on three distinct metabolic pathways.

How Each Receptor Contributes​

• GLP-1 receptor: Slows gastric emptying, reduces appetite through central nervous system signaling, and promotes glucose-dependent insulin secretion. This is the proven pathway behind semaglutide's success.

• GIP receptor: Enhances insulin release after meals, supports lipid metabolism, and may help buffer against the nausea that GLP-1 activation produces. GIP's role in fat cell signaling is increasingly recognized as a contributor to body composition improvements.

• Glucagon receptor: This is what sets retatrutide apart. Glucagon activation increases resting energy expenditure (your body burns more calories even at rest), promotes hepatic fat oxidation (your liver breaks down stored fat more efficiently), and drives lipolysis in adipose tissue. In animal models, glucagon receptor activation also stimulated thermogenesis through brown fat tissue.

The combined effect is a drug that suppresses appetite from two angles (GLP-1 and glucagon), improves how your body handles glucose and lipids (all three receptors), and actively ramps up calorie burning (primarily glucagon). No other medication currently in development or on the market addresses all three pathways simultaneously.

Clinical Trial Results: What the Data Shows​

Phase 2: The NEJM Study That Started the Buzz​

Published in the New England Journal of Medicine in August 2023, the Phase 2 obesity trial enrolled 338 adults with a BMI of 30 or higher (or 27+ with a weight-related condition) and no type 2 diabetes. Participants received weekly subcutaneous injections of retatrutide at 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, for 48 weeks. The results were striking.

At 48 weeks, the 12 mg group achieved an average weight loss of 24.2% of body weight, equivalent to roughly 58 pounds. Even more notable: 100% of participants in both the 8 mg and 12 mg groups lost at least 5% of body weight, and 83% in the 12 mg group lost 15% or more. Weight loss had not plateaued by week 48, suggesting the full effect may require longer treatment.

Beyond the scale, retatrutide produced significant improvements in systolic and diastolic blood pressure, triglycerides, LDL cholesterol, fasting glucose, and insulin levels. Perhaps most impressively, a substudy of participants with fatty liver disease (MASLD) showed liver fat reductions of up to 82% at 24 weeks, with 86% of participants on the 12 mg dose achieving normal liver fat levels (below 5%). These liver findings, published in Nature Medicine in 2024, positioned retatrutide as one of the most potent pharmacological interventions for fatty liver disease ever studied.

Phase 3: TRIUMPH-4 Sets a New Record​

In December 2025, Eli Lilly released the first Phase 3 results from the TRIUMPH program. The TRIUMPH-4 trial enrolled 445 adults with obesity and knee osteoarthritis, randomized to retatrutide 9 mg, 12 mg, or placebo for 68 weeks. Both doses met all primary and secondary endpoints.

Participants on the 12 mg dose lost an average of 28.7% of their body weight, equivalent to 71.2 pounds (32.3 kg). The 9 mg group lost 26.4%. These figures represent the highest weight loss ever recorded for any obesity medication in a Phase 3 clinical trial. To put that in perspective, the average participant went from about 249 pounds at baseline to approximately 177 pounds.

TRIUMPH-4 also demonstrated powerful effects on osteoarthritis pain, with WOMAC pain scores dropping by up to 75.8%. More than 1 in 8 retatrutide-treated patients were completely free of knee pain by the end of the trial. Cardiovascular risk markers improved significantly as well: non-HDL cholesterol, triglycerides, and high-sensitivity C-reactive protein all fell, and the highest dose lowered systolic blood pressure by 14 mmHg.

TRANSCEND-T2D-1: Triple Agonist Delivers in Diabetes​

The most recent data, released in March 2026, comes from TRANSCEND-T2D-1, which enrolled 537 adults with type 2 diabetes and inadequate blood sugar control. Over 40 weeks, retatrutide reduced A1C by 1.7% to 2.0% across dose groups (versus 0.8% with placebo). Participants on the 12 mg dose lost an average of 36.6 pounds (16.8% of body weight), and weight loss had still not plateaued at week 40. For comparison, tirzepatide achieves A1C reductions of 2.0-2.4% in the SURPASS trials, and semaglutide reaches roughly 1.5-1.8% in SUSTAIN.

How Retatrutide Compares: Semaglutide, Tirzepatide, and Beyond​

For men evaluating their options, a side-by-side comparison helps put retatrutide's data in context. Keep in mind that no head-to-head trials have been conducted between these agents, so all comparisons are indirect across different study populations.

Feature	Semaglutide	Tirzepatide	Retatrutide
Receptor Targets	GLP-1	GLP-1 + GIP	GLP-1 + GIP + Glucagon
Brand Names	Ozempic / Wegovy	Mounjaro / Zepbound	Investigational (not FDA-approved)
Max Weight Loss	~15-17% (68 wks)	~21-23% (72 wks)	~28.7% (68 wks)
Liver Fat Impact	Moderate reduction	Significant reduction	Up to 86% reduction
Energy Expenditure	No direct effect	No direct effect	Increases via glucagon
FDA Status	Approved	Approved	Phase 3 trials
Administration	Weekly SC injection	Weekly SC injection	Weekly SC injection

The pattern is clear: each generation of incretin-based therapy that adds receptor targets has produced greater weight loss. Semaglutide proved that GLP-1 agonism alone could produce meaningful results. Tirzepatide showed that adding GIP amplified those results. Retatrutide suggests that glucagon is the third piece of the metabolic puzzle.

Is Retatrutide Safe? Side Effects and the New Dysesthesia Signal​

Safety is the question that matters most for anyone considering retatrutide, and the honest answer is: the data looks promising but is still incomplete.

Standard GI Side Effects​

Like all GLP-1 class drugs, retatrutide causes gastrointestinal symptoms that are dose-related and most pronounced during escalation. In TRIUMPH-4, nausea occurred in 38-43% of retatrutide-treated participants (versus 11% with placebo), diarrhea in 33-35%, vomiting in 20-21%, and constipation in 22-25%. Most of these effects were mild to moderate and improved over time. Starting at a low dose (2 mg) and escalating gradually every four weeks significantly reduces the severity of GI symptoms.

Dysesthesia: A Newly Identified Safety Signal​

TRIUMPH-4 flagged a side effect not seen in Phase 2: dysesthesia, described as an abnormal sense of touch, tingling, tenderness, or altered skin sensation. It occurred in 8.8% of patients on the 9 mg dose and 20.9% on the 12 mg dose, compared to just 0.7% with placebo. This is a clinically meaningful rate that distinguishes retatrutide from other GLP-1 class medications.

Lilly has reported that dysesthesia events were generally mild and rarely led to treatment discontinuation. The signal is being monitored across all ongoing TRIUMPH trials. In the more recent TRANSCEND-T2D-1 trial, dysesthesia rates were lower: 2.3-4.5% across retatrutide doses. This difference may reflect the shorter treatment duration (40 versus 68 weeks) or the different patient population (diabetes patients with lower weight loss). Whether the FDA will require specific labeling around dysesthesia remains to be seen.

What We Don't Know Yet​

• Long-term cardiovascular outcomes: Glucagon receptor activation can raise heart rate. The TRIUMPH-Outcomes cardiovascular outcomes trial (10,000 participants) is ongoing but won't report for years.

• Bone mineral density: Rapid, significant weight loss can reduce bone density. No long-term bone data from retatrutide trials has been published.

• Weight regain after stopping: Data from other GLP-1 drugs suggest that most patients regain significant weight after discontinuation. Whether retatrutide's glucagon component changes this trajectory is unknown.

• Cancer risk: Like other GLP-1 drugs, retatrutide carries a precautionary note about thyroid C-cell tumors seen in rodent studies. People with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 should not use it.

Retatrutide Dosing: What the Clinical Trials Used​

Important: Retatrutide is not FDA-approved. It is an investigational compound legally available only through Lilly's clinical trials. The dosing information below is provided for educational purposes only. Any use outside of clinical trials is at the individual's own risk and should involve physician oversight.

Clinical Trial Dose Arms​

Phase 2 tested four dose levels: 1 mg, 4 mg, 8 mg, and 12 mg, all administered once weekly by subcutaneous injection. Phase 3 (TRIUMPH) studies tested 9 mg and 12 mg as therapeutic doses, with 4 mg evaluated as a potential maintenance dose. All arms used the same gradual escalation approach:

• Weeks 1-4: 2 mg weekly
• Weeks 5-8: 4 mg weekly
• Weeks 9-12: 6 mg weekly (for 9 mg target)
• Weeks 9-12: 6 mg, then Weeks 13-16: 9 mg weekly (for 12 mg target)

The gradual escalation over 12-16 weeks is not optional padding. It's essential for managing GI side effects. Phase 2 data showed that starting at 4 mg instead of 2 mg significantly increased nausea and vomiting rates. Slower titration lets the body adapt to each new dose level before increasing further.

What ExcelMale Community Members Report​

Forum members who've tried retatrutide through research peptide sources (a practice that comes with significant quality and safety risks) report a range of experiences. Some describe it as the best-tolerated GLP-1 class drug they've used, noting appetite suppression with noticeably less nausea than semaglutide or tirzepatide. Others report significant early weight loss (8 pounds in two weeks at just 2 mg). Several users split their weekly dose into two injections, reporting smoother appetite control and fewer GI symptoms.

One consistent observation from the community: retatrutide seems to shift food preferences away from fatty foods and toward carbohydrate-based meals (rice, potatoes, fruit). Multiple members mention increased energy compared to semaglutide. However, some report blood sugar drops after exercise, particularly during workouts, which makes dietary management more complex for active individuals.

Realistic Weight Loss Expectations​

Based on Phase 2 and Phase 3 data combined, here's what the evidence supports for weight loss timelines at therapeutic doses (8-12 mg):

• Weeks 1-12 (dose escalation): 5-10% body weight loss. Most of this period involves gradual dose increases, so the full metabolic effect hasn't kicked in yet.
• Weeks 12-24: The primary window of rapid weight loss, typically reaching 15-18% of baseline body weight.
• Weeks 24-48: Continued loss at a slower rate, reaching 22-24% in Phase 2 data.
• Weeks 48-68: Phase 3 data suggests additional loss beyond 48 weeks, reaching 26-29% at the highest dose. In TRIUMPH-4, weight loss curves had still not fully plateaued at 68 weeks.

Several factors influence individual results: starting BMI (higher BMI typically correlates with greater absolute weight loss), dietary adherence, physical activity level, dose, and genetic factors affecting receptor sensitivity. The most important variable may be diet quality during treatment. Retatrutide reduces appetite, but it doesn't make nutritional choices for you. Prioritizing protein intake (1 g per pound of lean body mass is a reasonable target) helps preserve muscle during rapid weight loss.

Body Composition: Fat Loss vs. Muscle Preservation​

A critical question for men on TRT: how much of the weight loss is fat versus muscle? A body composition substudy published in The Lancet Diabetes & Endocrinology in 2025 provided reassuring data. Using DEXA scanning in participants with type 2 diabetes, researchers found that roughly 62-75% of total weight loss came from fat mass, with 25-38% from lean mass. This ratio aligns with what's seen in bariatric surgery and other pharmacological interventions producing similar magnitudes of weight loss.

Importantly, retatrutide demonstrated preferential reduction of visceral adipose tissue (the metabolically dangerous fat around organs) compared to subcutaneous fat. For men on TRT who are concerned about body composition, this visceral fat targeting is particularly valuable. Testosterone's anabolic effects on muscle may further mitigate lean tissue losses. Combining retatrutide with resistance training and adequate protein intake represents the most logical strategy for optimizing the fat-to-muscle ratio during treatment.

Liver Fat and Metabolic Health: Retatrutide's Most Impressive Finding​

While the weight loss numbers grab headlines, retatrutide's effect on liver fat may ultimately prove to be its most significant clinical contribution. Fatty liver disease (MASLD) affects an estimated 38% of the global population and is a leading driver of liver transplants. Until recently, no highly effective pharmacological treatment existed.

In the Phase 2 MASLD substudy, participants with 10% or greater liver fat at baseline received retatrutide for 48 weeks. The results were remarkable: liver fat decreased by 81.4% to 86% from baseline in the 8 mg and 12 mg groups. Over 85% of participants on higher doses achieved normal liver fat levels (below 5%), compared to 0% of those on placebo. These reductions correlated strongly with improvements in insulin sensitivity, triglycerides, and inflammatory markers.

Researchers attribute this effect to a combination of overall weight loss and glucagon receptor-mediated hepatic fat oxidation. Glucagon directly promotes the liver's ability to break down and clear stored fat, an action that GLP-1 agonists alone do not produce as effectively. For men on TRT who may have elevated liver fat due to metabolic syndrome, insulin resistance, or previous steroid use, this effect has practical significance beyond the study population.

Combining Retatrutide with TRT: What ExcelMale Members Should Know​

No clinical trial has specifically studied the combination of retatrutide and testosterone replacement therapy. However, the pharmacological profiles of these medications don't suggest dangerous interactions, and the ExcelMale community is accumulating real-world experience with the combination.

Potential Synergies​

• Muscle preservation: Testosterone's anabolic effects may counteract the lean tissue losses seen during aggressive caloric deficits. For men on stable TRT, this provides a theoretical advantage over non-TRT patients using retatrutide.

• Visceral fat targeting: Both testosterone and retatrutide preferentially reduce visceral fat. The combination may accelerate improvements in metabolic syndrome markers like waist circumference, insulin resistance, and liver fat.

• SHBG changes: Significant weight loss typically increases SHBG, which can bind more free testosterone and reduce its bioavailability. Men on TRT should monitor free testosterone and SHBG levels during retatrutide treatment and adjust TRT doses if needed.

• Estradiol management: Rapid fat loss reduces aromatase activity, which may lower estradiol levels. Men using aromatase inhibitors may need to reduce or discontinue them as body fat decreases.

Practical Monitoring During Treatment​

If you're on TRT and considering adding a GLP-1 class medication (including retatrutide if/when it becomes available), work with your prescriber to monitor: total and free testosterone, SHBG, estradiol (sensitive assay), fasting insulin and glucose, comprehensive metabolic panel (including liver enzymes), lipid panel, and body composition via DEXA if accessible. Lab work every 8-12 weeks during active weight loss is reasonable, with adjustments to TRT protocol as your metabolic profile changes.

Availability and Access: Where Things Stand​

Retatrutide is not FDA-approved and is not available through standard prescription channels. The only legal way to obtain pharmaceutical-grade retatrutide is through enrollment in one of Lilly's clinical trials. The TRIUMPH program has enrolled over 5,800 participants across multiple trials, with seven additional Phase 3 readouts expected throughout 2026.

Some compounding pharmacies and research peptide suppliers offer products labeled as retatrutide. These carry significant risks: the compound may not actually contain retatrutide or may contain impurities, dosing accuracy is unverifiable, and no regulatory oversight ensures quality or sterility. If you choose to explore these sources despite the risks, look for suppliers that provide certificates of analysis (COA) from independent third-party testing, and insist on HPLC purity verification.

Based on current timelines, Lilly is expected to submit a New Drug Application (NDA) to the FDA in late 2026 or early 2027, with potential approval following a standard 10-12 month review cycle. If all goes according to plan, retatrutide could become commercially available by late 2027.

Frequently Asked Questions​

How does retatrutide compare to Ozempic?​

Retatrutide targets three receptors (GLP-1 + GIP + glucagon) versus Ozempic's single GLP-1 target. In indirect comparisons across trials, retatrutide produces roughly 28% weight loss at 68 weeks versus approximately 15% with semaglutide. Retatrutide also shows far greater liver fat reduction and may increase resting energy expenditure through its glucagon component. However, semaglutide has years of real-world safety data and cardiovascular outcomes evidence that retatrutide hasn't yet generated.

Is retatrutide approved by the FDA?​

No. As of March 2026, retatrutide remains an investigational compound in Phase 3 clinical trials. No regulatory agency anywhere in the world has approved it. FDA submission is anticipated in late 2026 or early 2027.

Can I use retatrutide if I'm on TRT?​

No clinical trial has studied this specific combination. Based on pharmacological profiles, there's no known dangerous interaction. However, significant weight loss affects hormone metabolism: SHBG may increase (reducing free testosterone), estradiol may decrease (requiring aromatase inhibitor adjustments), and insulin sensitivity improvements may alter your overall metabolic profile. Close monitoring with your prescriber is essential.

What's the difference between GLP-1, GLP-2, and GLP-3?​

GLP-1 and GLP-2 are actual hormones. GLP-1 regulates appetite and insulin; GLP-2 promotes intestinal growth and nutrient absorption. "GLP-3" is not a hormone. It's informal shorthand used online to describe triple-agonist peptides like retatrutide that act on three receptors (GLP-1, GIP, and glucagon).

How long does it take to see results with retatrutide?​

Based on clinical trial data, appetite reduction typically begins within the first one to two weeks. Noticeable weight loss (2-5% of body weight) occurs by weeks four to eight during dose escalation. The most rapid weight loss period is weeks 12-24 after reaching the full therapeutic dose. Weight loss continues through at least 68 weeks without clear plateau at higher doses.

Related ExcelMale Forum Discussions​

Explore these community discussions for additional insights and real-world experiences:
Retatrutide: A Game Changer in Obesity Pharmacotherapy — Detailed thread covering retatrutide mechanisms, Phase 2/3 trial data, and member experiences with the triple agonist
Retatrutide: The Next Generation Triple Agonist Transforming Weight Management — In-depth analysis of retatrutide for men on TRT, including body composition data and practical protocol recommendations
Looking for Retatrutide Experiences — Community thread where members share firsthand retatrutide experiences, dosing protocols, and tips for managing side effects
Stacking with Retatrutide — Discussion of combining retatrutide with other peptides and supplements for cutting and maintenance phases
On Retatrutide and Not Feeling Effects — Troubleshooting thread for members who haven't experienced expected appetite suppression or weight loss

Key References​

1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. [Link]
2. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes. Lancet. 2023;402(10401):529-544. [Link]
3. Sanyal AJ, Frias JP, Thomas MK, et al. Triple Hormone Receptor Agonist Retatrutide for MASLD: A Randomized Phase 2a Trial. Nat Med. 2024;30(7):2037-2048. [Link]
4. Eli Lilly and Company. TRIUMPH-4 Phase 3 Topline Results: Retatrutide Delivered Weight Loss Up to 71.2 lbs. Press Release, December 11, 2025. [Link]
5. Eli Lilly and Company. TRANSCEND-T2D-1 Phase 3 Topline Results: Significant Reductions in A1C and Weight. Press Release, March 19, 2026. [Link]
6. Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the Treatment of Obesity, OSA and Knee OA: Rationale and Design of the TRIUMPH Trials. Diabetes Obes Metab. 2026;28(1):83-93. [Link]
7. Coskun T, Urva S, Roell WC, et al. LY3437943: A Novel Triple Glucagon, GIP, and GLP-1 Receptor Agonist. Cell Metab. 2022;34(9):1234-1247. [Link]
8. Abouelmagd AA, et al. Efficacy and Safety of Retatrutide for Obesity Treatment: A Systematic Review and Meta-Analysis. Proc (Bayl Univ Med Cent). 2025;38(3):291-303. [Link]

Medical Disclaimer​

This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational compound not approved by the FDA or any regulatory agency. It is legally available only to participants in Eli Lilly's clinical trials. Information about dosing and effects is provided strictly for educational purposes based on published clinical data and should not be interpreted as a recommendation to use this compound. Always consult a qualified healthcare provider before starting, changing, or stopping any medication or supplement regimen.

About ExcelMale​

ExcelMale.com is the internet's leading community for men's health, testosterone optimization, and hormone replacement therapy. With over 24,000 members and more than 20 years of archived discussions, ExcelMale provides a unique resource combining evidence-based medical information with real-world patient experiences. Founded by Nelson Vergel, a chemical engineer, pharmaceutical consultant, and 40+ year patient advocate, the forum bridges the gap between clinical research and practical application.
Nelson is the author of Testosterone: A Man's Guide and Beyond Testosterone, both widely regarded as essential reading for men navigating hormone optimization. For more information, visit ExcelMale.com.